Trial Profile

A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bardoxolone methyl (Primary)
Indications Pulmonary arterial hypertension
Focus Registrational; Therapeutic Use
Acronyms CATALYST
Sponsors Reata Pharmaceuticals

Most Recent Events

15 Dec 2020 Status changed from suspended to completed.
10 Nov 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
10 Jul 2020 This trial has been discontinued in Germany, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com